Health Catalyst Hands the CEO Job to Simeon Kohl

Health Catalyst, Inc. (HCAT) said Tuesday that Simeon Kohl has been appointed chief executive officer, president and a director effective September 14, 2026, while Ben Albert becomes chief business officer.

Health Catalyst, Inc. (HCAT) is changing the person at the top. The healthcare intelligence company said Tuesday that Simeon Kohl has been appointed chief executive officer, president and a member of the board, with the appointment taking effect on September 14, 2026. In the same announcement, Health Catalyst said Ben Albert will become chief business officer.

Two things are worth separating here. One is the title change itself, which is straightforward. The other is the structure it implies: a CEO who also holds the president role and a board seat, and a chief business officer whose remit sits alongside him rather than beneath a layer of divisional management. Companies that combine the chief executive and president roles in one person are usually signalling that they want decisions made faster and in fewer places.

What the company actually said

The disclosure, reported by Nasdaq Markets, is narrow: Kohl takes CEO, president and director titles from September 14, 2026, and Albert moves into the chief business officer seat. Health Catalyst described itself in the announcement as a healthcare intelligence company. No financial guidance, restructuring plan or strategic review accompanied the leadership news.

That matters for how investors should read it. A CEO announcement made on its own, without a simultaneous revision to outlook, is a different signal from one bundled with a profit warning. It tells you the board has settled the succession question and wants the market to absorb that fact cleanly, before any strategic decisions the new chief executive makes get attributed to him.

Where the shares stand going in

Health Catalyst last traded at 1.69, down 1.17% on the day, having closed the prior session at 1.71. The stock's range in that session was 1.67 to 1.71 — a narrow band, and one that tells you the shares were moving on very little. Those figures are as of the last trade on Friday, September 4, 2026, at 20:00 GMT; the market was closed at the time of writing.

A share price under two dollars is not, in itself, a verdict on a business. But it does change the mechanics of what a new chief executive is walking into. At that level, small absolute moves are large percentage moves, index and institutional mandates that screen on minimum price can drop out, and the cost of raising equity capital rises sharply because every dollar raised dilutes existing holders more. A CEO arriving at a low-priced stock generally has a narrower set of tools than one arriving at a richly valued one — organic cash generation and cost discipline tend to matter more than acquisition currency.

For context on the tape Kohl inherits: the S&P 500 tracker (SPY) closed at $770.19, down 0.39%, the Dow tracker (DIA) at $534.08, down 0.53%, and the Nasdaq 100 tracker (QQQ) at $718.96, up 0.18%. Broad indexes were mixed and close to flat. Whatever has happened to Health Catalyst's share price, it has not been the market doing it.

Why the chief business officer role is the part to watch

The Albert appointment is easy to skip past and probably shouldn't be. A chief business officer title typically consolidates commercial responsibility — partnerships, revenue-generating relationships, business development — into a single executive who reports to the CEO. Creating or filling that seat at the same moment a new chief executive arrives usually means the board has decided that the growth problem and the operating problem need different owners.

In healthcare data and analytics specifically, the commercial cycle is slow. Health systems buy on multi-year contracts, procurement runs through committees, and expansion within an existing customer is usually cheaper to win than a new logo. A chief business officer's scorecard in that environment is less about signing headline deals than about renewal rates, contract expansion and the length of the sales cycle. Those are the metrics that would show whether the reshuffle is working, and they show up in results rather than press releases.

What investors should look for next

Health systems buy on multi-year contracts, procurement runs through committees, and expansion within an existing customer is usually cheaper to win than a new logo.

The immediate calendar item is September 14, 2026, when Kohl formally takes the role. After that, the questions are the standard ones for any incoming chief executive of a company whose stock has been marked down:

Whether the first full quarter under new leadership brings a change to guidance, a cost programme, or a restatement of strategic priorities.
Whether Kohl's board seat is accompanied by other board changes — a refreshed board often follows a CEO change and signals how deep the reset goes.
How the commercial line is drawn between the chief executive and the chief business officer, and whether that clarity shows up in bookings.
Whether the company addresses its share price level directly, which for sub-$2 stocks eventually becomes a listing and liquidity conversation as well as a valuation one.

A leadership handoff is a starting point, not a result

Executive changes are among the few corporate events that reliably move sentiment without changing a single number on the income statement. Nothing about Health Catalyst's revenue, margins or contract base is different on September 14 than it was on September 13. What changes is who is accountable, and what the market is willing to give them time to prove.

The honest read is that the announcement resolves an uncertainty rather than removing a problem. Investors now know who is running the company and who owns the commercial side. The evidence of whether that arrangement works will take at least a couple of reporting periods to arrive — and until it does, the share price is likely to trade on the same things it traded on before.

Key facts

Ticker and last price: HCAT — 1.69, down 1.17%, as of the close on Sept 4, 2026, 20:00 GMT
New CEO: Simeon Kohl, appointed CEO, president and director
Effective date: September 14, 2026
Second appointment: Ben Albert to become chief business officer

Frequently asked questions

Who is Health Catalyst's new chief executive?

Simeon Kohl has been appointed chief executive officer of Health Catalyst, Inc. (HCAT). He also takes the titles of president and a director of the company. Health Catalyst announced the appointment on Tuesday, and it becomes effective on September 14, 2026. The company describes itself as a healthcare intelligence business.

What happens to Ben Albert?

Health Catalyst said Ben Albert will become the company's chief business officer. The company did not detail the specific responsibilities attached to the role in its announcement. A chief business officer title generally consolidates commercial functions such as partnerships, business development and revenue-generating relationships under a single executive reporting to the chief executive.

When does the change take effect?

The appointment of Simeon Kohl as chief executive officer, president and director takes effect on September 14, 2026. Health Catalyst disclosed the leadership changes on Tuesday. No accompanying guidance revision, restructuring plan or strategic review was announced alongside the executive changes, which makes the disclosure a standalone succession announcement.

Where does the Health Catalyst share price stand?

HCAT last traded at 1.69, down 1.17% on the day, against a previous close of 1.71. The session range was 1.67 to 1.71. Those figures are as of the last trade on September 4, 2026, at 20:00 GMT, when the market was closed. The narrow range suggests low news flow at the time.

Does a CEO change usually move a stock?

Executive changes can shift sentiment without altering any reported financial figure. Nothing about a company's revenue, margins or contract base changes on the day a new chief executive starts. What changes is accountability and the market's willingness to extend time. The evidence typically takes at least two reporting periods to appear in results.

Why does a low share price matter for a new CEO?

At a share price under two dollars, small absolute moves become large percentage moves, some institutional mandates that screen on minimum price can no longer hold the stock, and raising equity capital dilutes existing shareholders more heavily. That tends to push a new chief executive toward organic cash generation and cost discipline rather than acquisitions.

Sources

Health Catalyst Names Simeon Kohl New CEO As Ben Albert To Become Chief Business Officer — Nasdaq Markets

Photo: Pavel Danilyuk · Pexels Licence — source